secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0001104659-22-109063
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec launches PEDMARK in US for cisplatin-induced hearing loss in pediatric patients
--------------------------------------------------------------------------------

- PEDMARK is the first and only FDA-approved therapy to reduce cisplatin-induced ototoxicity in pediatric patients aged 1 month+ with localized solid tumors.
- Launch follows FDA approval in September 2022; based on Phase 3 trials COG ACCL0431 and SIOPEL 6.
- Annual estimated 10,000+ US/European children receive platinum chemo; ~60% may develop permanent hearing loss without PEDMARK.
- Fennec HEARS program launched to provide patient financial support, access coordinators, and prescription drug assistance.
- EMA is currently evaluating Marketing Authorization Application for PEDMARQSI (sodium thiosulfate) in Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922109063/0001104659-22-109063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922109063/tm2228337d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-109063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer